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Abstract The Rotterdam Study is a prospective cohort
study ongoing since 1990 in the city of Rotterdam in The
Netherlands. The study targets cardiovascular, endocrine,
hepatic, neurological, ophthalmic, psychiatric, dermato-
logical, oncological, and respiratory diseases. As of 2008,
14,926 subjects aged 45 years or over comprise the Rot-
terdam Study cohort. The ﬁndings of the Rotterdam Study
have been presented in over a 1,000 research articles and
reports (see www.erasmus-epidemiology.nl/rotterdamstudy).
This article gives the rationale of the study and its design. It
also presents a summary of the major ﬁndings and an update
of the objectives and methods.
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Introduction
The Rotterdam Study was designed in the mid-1980s as a
response to the demographic changes that were leading to
an increase of the proportion of elderly people in most
populations [1]. It was clear that this would produce a
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diseases cluster at the end of life, and that to discover the
causes of diseases in the elderly one would have to study
risk factors of those diseases [2]. A major approach to
ﬁnding causes is the prospective follow-up study, which
has proven quite effective in ﬁnding causes of heart disease
and cancer.
The design of the Rotterdam Study
The design of the Rotterdam Study is that of a prospective
cohort study among, initially, 7,983 persons living in the
well-deﬁned Ommoord district in the city of Rotterdam in
The Netherlands (78% of 10,215 invitees). They were all
55 years of age or over and the oldest participant at the
start was 106 years [3]. The study started with a pilot phase
in the second half of 1989. From January 1990 onwards
participants were recruited for the Rotterdam Study.
Figure 1 gives a diagram of the various cycles in the study.
In 2000, 3,011 participants (out of 4,472 invitees) who had
become 55 years of age or moved into the study district
since the start of the study were added to the cohort. In
2006, a further extension of the cohort was initiated in
which 3,932 subjects were included, aged 45–54 years, out
of 6,057 invited, living in the Ommoord district. By the end
of 2008, the Rotterdam Study therefore comprised 14,926
subjects aged 45 years or over [4, 5]. The overall response
ﬁgure for all three cycles at baseline was 72.0% (14,926 of
20,744).
The participants were all examined in some detail at
baseline. They were interviewed at home (2 h) and then
had an extensive set of examinations (a total of 5 h) in a
specially built research facility in the centre of their dis-
trict. These examinations focussed on possible causes of
invalidating diseases in the elderly in a clinically state-of-
the-art manner, as far as the circumstances allowed. The
emphasis was put on imaging (of heart, blood vessels, eyes,
Fig. 1 Diagram of examination cycles of the Rotterdam Study (RS).
RS-I-1 refers to the baseline examination of the original cohort (pilot
phase 07/1989–12/1989; cohort recruitment 01/1990–09/1993). RS-I-
2, RS-I-3, RS-I-4, and RS-I-5 refer to re-examination of the original
cohort members. RS-II-1 refers to the extension of the cohort with
persons in the study district that became 55 years since the start of the
study or those of 55 years or over that migrated into the study district.
RS-II-2 refers to re-examination of the extension cohort. RS-III-1
refers to the baseline examination of all persons aged 45 years and
over living in the study district that had not been examined (i.e.,
mainly comprising those aged 45–60 years). RS-II-3 and RS-III-2
refer to ongoing and future re-examinations. Examination RS-I-4 and
RS-II-2 were conducted as one project and feature an identical
research program. Similarly, examinations RS-I-5, RS-II-3, and RS-
III-2 will share the same program items
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123skeleton and later brain) and on collecting bodily ﬂuids that
enabled further in-depth molecular and genetic analyses.
These examinations were repeated every 3–4 years in
characteristics that could change over time. And so there
were examination cycles from 1990 to 1993, from 1993 to
1995, from 1997 to 1999, from 2000 to 2001, from 2002 to
2004, from 2004 to 2005, from 2006 to 2008, and from
2009 to January 2011 (Fig. 1). In February 2011 the third
examination cycle for the second cohort (RS-II-3) was
started.
The participants in the Rotterdam Study are followed
for a variety of diseases that are frequent in the elderly
(and many are also in the not so elderly): coronary heart
disease, heart failure and stroke, Parkinson disease,
Alzheimer disease and other dementias, depression and
anxiety disorders, macular degeneration and glaucoma,
respiratory diseases, liver diseases, diabetes mellitus, oste-
oporosis, dermatological diseases and cancer. The Rotter-
dam Study has been approved by the institutional review
board (Medical Ethics Committee) of the Erasmus Medical
Center and by the review board of The Netherlands Min-
istry of Health, Welfare and Sports. The approval has been
renewed every 5 years, as well as with the introduction of
major new elements in the study (e.g., MRI investigations).
In the remainder of this article the objectives and major
ﬁndings will be presented with an update of the research
methods for cardiovascular diseases, dermatological dis-
eases, endocrine diseases, liver diseases, neurological
diseases, ophthalmic diseases, psychiatric diseases, respi-
ratory diseases, as well as for genetic and biomarker studies
and for pharmaco-epidemiologic studies. For relevant
recent EJE references see [6–32].
Cardiovascular diseases
Objectives
Research on the epidemiology of cardiovascular disease
focuses on the etiology and prediction of coronary heart
disease and on cardiovascular conditions at older age, like
heart failure and atrial ﬁbrillation. Putative risk factors
include three groups, endocrine factors, factors involved in
hemostasis, inﬂammation and endothelial function, and
genetic risk factors. A major focus is on non-invasive
assessment of atherosclerosis to improve prediction of
coronary heart disease, including measurement of coronary
calcium with electron-beam and multi-detection CT and
carotid plaque characterization by high-resolution MRI.
Cerebrovascular diseases, including stroke, are also investi-
gated in the Rotterdam Study. They are described under
Neurological diseases.
Major ﬁndings
Recognized and unrecognized myocardial infarction
We found that a high proportion of incident myocardial
infarctions remains clinically unrecognized. The incidence
rate of recognized myocardial infarction in the Rotterdam
Study was 5.0 per 1,000 person years. The incidence was
higher in men (8.4) than in women (3.1). The incidence
rate of unrecognized infarction was 3.8 per 1,000 person
years. Men (4.2) and women (3.6) had approximately
similar incidence. Hence, the proportion of unrecognized
infarction is lower in men (33%) than in women (54%)
[33].
Cardiovascular risk factors
Endocrine, inﬂammatory and hemostatic factors and risk of
coronary heart disease were addressed in several studies.
Subclinical hypothyroidism was an independent risk factor
of atherosclerosis and myocardial infarction in older
women [34]. Recently, we showed that amino-terminal
pro-B-type natriuretic peptide (NT-ProBNP) improved
cardiovascular and cerebrovascular risk prediction in an
older population [35]. Plasma C-Reactive protein (CRP)
and lipoprotein-associated phospholipase A2 (Lp-PLA2)
activity were independent predictors of coronary heart
disease [36, 37]. Early ﬁndings included the association of
tissue plasminogen activator (TPA) with incident coronary
heart disease [38].
Non-invasive measures of atherosclerosis
Multiple studies focused on the predictive value of non-
invasive measures of atherosclerosis for risk of coronary
heart disease. Strong associations with risk of coronary
heart disease were found for carotid intima-media thick-
ness [39], pulse wave velocity [40], and coronary calciﬁ-
cation as assessed by electron-beam CT [41]. The relatively
crude measures directly assessing plaques in the carotid
artery and abdominal aorta predict coronary heart disease
equally well as the more precisely measured carotid intima-
media thickness [42]. In subjects at intermediate risk of
cardiovascular disease, coronary calcium scoring proved to
be a powerful method to reclassify persons into more
appropriate risk categories [43].
Genetic studies
Genetic studies included candidate gene studies [44] and
more recently genome-wide association studies of clinical
disease and risk factor phenotypes. Genome-wide associ-
ation studies are primarily conducted in the context of the
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demiology (CHARGE) Consortium [45] of which major
ﬁndings are reported here. We identiﬁed 3 genetic loci
associated with uric acid concentration and gout [46]. We
also identiﬁed a signiﬁcant association between chronic
kidney disease and the UMOD gene which encodes Tamm-
Horsfall protein [47]. In the same consortium, we found
four genes for systolic blood pressure, six for diastolic
blood pressure and one for hypertension [48]. We found
multiple loci that inﬂuenced erythrocyte phenotypes in the
CHARGE Consortium [49]. Recently, we identiﬁed 18 loci
for CRP levels in a meta-analysis in more than 80,000
individuals from 25 studies. The study highlighted immune
response and metabolic regulatory pathways involved in
the regulation of chronic inﬂammation [50]. Novel asso-
ciations of multiple genetic loci with plasma levels of
factor VII, factor VIII, and von Willebrand factor were also
detected [51].
Heart failure and atrial ﬁbrillation
The Rotterdam Study enabled accurate assessment of the
incidence and lifetime risk of heart failure and atrial
ﬁbrillation in an elderly population [52, 53]. It was shown
that inﬂammation is associated with risk of heart failure
[54]. Subclinical atherosclerosis, cigarette smoking and
high-normal thyroid function were identiﬁed as new risk
factors of atrial ﬁbrillation [55–57]. In a large collaborative
study as part of the CHARGE consortium, we investigated
the genetic variation responsible for 6 traits related to
cardiac structure and function. We found two replicated
loci for left ventricular dimension and 5 replicated loci for
aortic root size [58]. Another topic of interest was the
search for genetic determinants of several rhythm and
conduction disturbances on the ECG, notably RR-interval,
QRS, and QT(c) interval, as well as PR-interval and atrial
ﬁbrillation, and sudden cardiac death. For example, we
identiﬁed several new loci for PR interval [59] and a new
gene (ZFHX3) associated with atrial ﬁbrillation [60]i na
meta-analysis of studies of the CHARGE consortium.
Methods update
Cardiovascular risk factors
Three groups of putative risk factors for cardiovascular
conditions are examined. The ﬁrst are endocrine factors,
including diabetes, sex hormones, thyroid gland and adre-
nal gland hormones and natriuretic peptides (e.g. [34, 35,
61]. The second group comprises factors involved in
hemostasis, inﬂammation and endothelial function (e.g.
[36–38]. The third group, and currently a major focus,
covers genetic factors in these areas. In addition to the
candidate gene approach, studies are more recently con-
ducted through the genome-wide association approach (e.g.
[46–51]. In genome-wide association studies, data from the
Rotterdam Study are often combined with those from other
studies in the context of the large collaborative CHARGE
consortium [45].
Non-invasive measures of atherosclerosis
At baseline and follow-up examinations, ultrasonographic
assessments of carotid intima-media thickness and carotid
plaques were conducted in all subjects [39]. At these
examinations, also measurements of the ankle-brachial
index and aortic calciﬁcation (on X-rays of the lumbar
spine) were performed [42]. Carotid-femoral pulse wave
velocity, a measure of aortic stiffness, was measured in all
subjects of RS-I-3 and RS-II-1 with an automatic device
(CompliorArtech Medicla) [40]. Measurements of coronary
calciﬁcation by electron-beam CT and more recently by
multi-detector CT (MDCT) were conducted from 1997
onwards in RS-I and RS-II [41, 43]. From 2003 to 2006,
MDCT was also used to quantify calciﬁcation in the aortic
arch and carotid arteries in RS-I and RS-II. Measurement
of carotid plaque components with high-resolution MRI
started in October 2007 and will be continued until per-
formance is completed in all subjects with carotid wall
thickening from RS-I, RS-II and RS-III.
Electrocardiographic, echocardiographic
and other ultrasound measurements
At every exam, 12-lead resting ECGs are made and pro-
cessed by the Modular ECG Analysis System (MEANS) to
obtain a series of ECG measurements [62]. Abdominal
aortic diameters were measured by ultrasound at baseline.
From 2002 onwards (RS-I-4), repeated ultrasonographic
measurements are conducted of structural and functional
parameters of the left ventricle and atrium [63]. From 2009
(RS-I-5), measurements of structure and function of the
right side of the heart are also performed to diagnose
subclinical pulmonary hypertension.
Clinical follow-up
Data on clinical cardiovascular outcomes are collected
through an automated follow-up system. The follow-up
system involves linkage of the study base to ﬁles from
general practitioners in the study area and subsequent
collection of information from letters of medical special-
ists and discharge reports in case of hospitalisation. With
respect to the vital status of participants, information is
also obtained regularly from the municipal health authori-
ties in Rotterdam. After notiﬁcation, cause and circumstances
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123of death are established by questionnaire from the general
practitioners. Clinical cardiovascular outcomes are coded
by study physicians and medical experts in the ﬁeld
according to the International Classiﬁcation of Diseases,
10th edition (ICD-10). Incident coronary heart disease is
deﬁned as the occurrence of a fatal or nonfatal myocardial
infarction (I21), other forms of acute (I24) or chronic
ischemic (I25) heart disease, sudden (cardiac) death (I46
and R96), death caused by ventricular ﬁbrillation (I49), or
death resulting from congestive heart failure (I50) during
follow-up [37]. Other outcomes include heart failure [52]
and atrial ﬁbrillation [53]. For additional EJE references
concerning cardiovascular disease see [64–111].
Dermatological diseases
Objectives
Dermatoepidemiologic research in the Rotterdam Study
focuses on the frequency of the most common skin con-
ditions as well as on genetic and environmental factors
associated with these skin diseases. The emphasis of the
skin component is on cutaneous malignancies such as basal
and squamous cell carcinomas (BCC and SCC, respec-
tively) and their precursor lesions, and inﬂammatory der-
matoses such as eczema and psoriasis. In addition to skin
diseases, we examine the contribution of genetics and
environmental exposures to the skin fenotype (e.g., skin
pigmentation, wrinkling and photodamage) of the cohort
members.
Methods
In 2010, dermatology was introduced in the Rotterdam
Study. To the home interview several items have been
added questioning ultraviolet light exposure, history of
(personal and familial) psoriasis, history of skin cancer, the
diagnostic criteria of British association of dermatology for
atopic eczema, adjusted diagnostic criteria for psoriatic
arthritis.
A full body skin examination by physicians trained in
dermatology with a focus on the most common skin dis-
eases is the core contribution of dermatology. The clinical
presence and extent of speciﬁc skin diseases (i.e., actinic
keratosis, malignancies, psoriasis, xerosis, hand and ﬂex-
ural eczema, alopecia, and signs of chronic venous insuf-
ﬁciency based on the ‘C’ of the CEAP classiﬁcation) at
time of examination is assessed in a standardized fashion.
Other dermatological diseases will just be noted.
The extent of facial photodamage and wrinkling are
scored using a validated photonumeric scale and the Glogau
scale, respectively. The Norwood-Hamilton classiﬁcation
and the Ludwig classiﬁcation is used for male and female
pattern hair loss, respectively. Fully standardized
3-dimensional photographs (Premier 3dMDface3-plus
UHD, Atlanta, USA) of the face are taken to further assess
skin characteristics. The pigmentation of the facial skin and
at the inner side of the upper arm are measured using a
spectrophotometer (Konica Minolta Sensing, spectropho-
tometer CM-700d, Singapore). In a subgroup of the cohort,
skin topography measures will be taken at the inner side of
the upper arm as well.
As for other cancers, pathology data of the cutaneous
malignancies is obtained from a network of pathology
laboratories in Rotterdam and its surroundings and the
Dutch pathology database (PALGA). In a further attempt to
identify cohort members with psoriasis, medical ﬁles and
dispenses at pharmacies will be studied.
Major ﬁndings
The prevalence of single and multiple BCC was studied in
the Rotterdam Study and showed that a total of 524 patients
(4.8% of included population) had developed this type of
keratinocytic cancer and that 31.1% had developed more
than one tumor during observation [112]. A multi-failure
survival model suggested that people with red hair and
higher levels of education, and those who had their ﬁrst
BCC at younger age were signiﬁcantly more likely to
develop multiple malignancies. In a candidate gene
approach, Vitamin D-binding protein (VDBP) genotype
was not associated with (multiple) BCC development,
except possibly in the youngest age-group (A/T variant of
rs7041 was associated with; adjusted HR = 1.88, 95% CI
1.10–3.20), whereas homozygote Gc1s carriers had a sig-
niﬁcantly lower BCC risk; adjusted HR = 0.53, 95% CI
0.31–0.91) [113].
In a pharmaco-epdemiologic study, the hypothesis that
(prior) exposure to drugs such as high-ceiling diuretics
increase skin cancer risk due to enhanced photosensitivity
of the skin was tested. In line with the hypothesis, use of
potassium sparing and thiazide agents were not and use of
high-ceiling diuretics was associated with an increased
hazard of BCC (highest quartile compared to non users;
HR 1.6, 95% CI 1.1–2.4).
Endocrine diseases
Objectives
The main objective of the programme of endocrine epi-
demiology research is to study frequency and etiology of
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ductive, thyroid, parathyroid, adrenal, and neuro-endocrine
pancreas) and the musculoskeletal system. These include
endocrine and locomotor diseases, including diabetes
mellitus, osteoporosis, osteoarthritis, growth-hormone deﬁ-
ciency, hypo- and hyper-thyroidism and parathyroidism.
The evaluation of risk factors for the above mentioned
conditions includes serum measurements (such as classical
hormones and other endocrine molecules) and genetic
determinants of endocrine factors and signalling pathways.
Major ﬁndings
We have provided epidemiological documentation on the
hormone, growth factor and biomarker proﬁles in the
general population and determined the association with
several diseases. Within the topics of locomotor diseases
and disability we have reported that heart failure, COPD,
diabetes mellitus and chronic disorders leading to loco-
motor complaints, are risk factors which contribute con-
siderably to locomotor disability [114, 115]. In relation to
osteoporosis we have determined the incidence of vertebral
[116] and non-vertebral fractures [117], and the relation-
ship between bone mineral density (BMD), BMD change
and the occurrence of fracture [117], as well as with heel
ultrasound measurements [118] and bone resorption
markers [119]. We have also studied the relation between
endogenous sex hormones and their binding factors, with
fractures [120], and showed that increased homocysteine
levels are a strong and independent risk factor for osteo-
porotic fractures [121]. We studied the relations between
osteoporosis and other chronic diseases like osteoarthritis
[122], cancer [123], atherosclerosis [124] and diabetes
[125, 126], and provided indications for the treatment and
diagnosis of osteoporosis. Lastly, we were part of several
large consortia studying epidemiological risk factors for
osteoporosis [127–129]. For osteoarthritis (OA) we have
shown how a new marker of disease (CTX-II), is associated
with the prevalence and the progression of radiographic
OA [130], independent of known clinical risk factors. In
addition, we have studied different aspects of OA disease
deﬁnition and classiﬁcation [131], evaluation of disease
progression [132] and determined the most prominent risk
factors leading to OA [133, 134]. We have also studied
inﬂammatory aspects of endocrine diseases like diabetes
mellitus [135], and the relations of hypo/hyperthyroidism
to cardiovascular and neurological disease [136]. We fur-
ther examined the inﬂuence of genetic variation in endo-
crine genes inﬂuencing hormone levels [137, 138],
interaction of genetic factors in relation to fracture risk
[138, 139], to cardiovascular risk factors [140] and to
neurological conditions [141]. Our team has played a
leading role in bringing together the global GENOMOS
consortium which has performed prospective meta-analy-
ses across many epidemiological cohorts for the most
prominent candidate genes for osteoporosis (see also
‘‘Genetic and biomarker studies’’).
Methods update
For all participants DXA-based BMD measurements of the
lumbar spine, dual hip and total body BMD, as well as
determination of body composition parameters are assessed
with a ProdigyTM total body fan-beam densitometer (GE
Lunar Corp, Madison, WI, USA). Hip structural analysis
[142] of DXA scans is available in a subset of participants,
while hip strength indexes (software by GE Lunar) are
determined for all scans. In the current follow-up cycle we
have introduced since 2009 iDXA measurements (GE
Lunar) which performs lumbar spine, dual hip and total
body scans. Measurements include L1–L4 BMD, bilateral
total hip and femoral neck BMD and total body BMD.
From the total body scan, we measure lean mass and fat
mass body composition, including total body, trunk, arm,
legs, and android and gynoid regions of interest. X-ray
examinations of vertebral bodies, hips, knees and hand/
wrist are obtained by a digitalized Fuji FCR system
(FUJIFILM Medical Systems) and assessed for the pres-
ence of fractures and/or degenerative changes of the joints.
Vertebral fractures are assessed using the qualitative
algorithm-based technique termed the ABQ method, an
update to the quantitative McCloskey–Kanis method [143].
Incident clinical fractures are obtained from computerized
records of the general practitioners and hospital registries
which are regularly checked by research physicians who
review and code the fracture information. Muscle strength
is assessed in all participants with a hand grip dynamometer.
The incidence and progression of OA is done using Kell-
gren scores obtained from X-rays of hip, knee, hands, en
spine. The complete set of X-rays is also available in
digitized form. Novel diagnostic assessments for OA are
currently underway using Magnetic Resonance Imaging
(MRI) on a large subset of the population. Several speciﬁc
biomarker assessments in blood/serum/plasma and urine
are done for the diagnosis and evaluation of risk factors of
endocrine and metabolic diseases. Candidate gene and
genome-wide association studies (GWAs) are actively
pursued within the scope of our research for many of the
above mentioned endocrine and locomotor traits and dis-
eases. Finally, validated questionnaires evaluating nutrient
intake (e.g., calcium and vitamins) and activities of daily
living, allow to evaluate the role of environmental factors
in endocrine conditions and locomotor diseases of the
elderly. For recent references in EJE see [144–172].
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123Liver diseases
Objectives
Fibrogenesis of the liver is most probably not only the
result of well known liver diseases, such as viral hepa-
titis, alcoholic liver disease or non-alcoholic fatty liver
disease (NAFLD), but rather a complex interaction
between a genetic predisposition and these liver disor-
ders. Liver research in the Rotterdam Study will concern
the association between these known causes of liver
disease and the occurrence, magnitude, and progression
of ﬁbrosis in combination with genetic and environ-
mental factors. Additional research focus will be on
NAFLD. NAFLD is considered the hepatic manifestation
of the metabolic syndrome and has become the most
common chronic liver disease in Western countries in
parallel with epidemics of obesity and type II diabetes
mellitus. We aim to study the occurrence and risk factors
of NAFLD in a general population and generate insight
into the association with cardiovascular morbidity and
mortality.
Methods
Abdominal ultrasound
From February 2009 trained technicians perform abdomi-
nal ultrasonography in Rotterdam Study participants.
Liver, biliary tract, gall bladder, spleen, pancreas, and
kidneys in combination with Doppler examination of
hepatic veins, hepatic artery and portal vein will be eval-
uated. All images are stored digitally and will be reevalu-
ated by an ultrasound trained physician.
Assessment of steatosis The diagnosis and grading of
liver steatosis will be based on ultrasonographic liver
brightness, hepatorenal echo contrast, deep attenuation and
vessel blurring [173].
Non alcoholic fatty liver is diagnosed by presence of
steatosis on ultrasound and exclusion of excessive alcohol
consumption, presence of viral hepatitis, use of fatty liver
inducing pharmacological agents, recent bariatric surgery
and a history of inﬂammatory bowel disease.
Assessment of ﬁbrosis Ultrasonographic evaluation of the
liver parenchyma and liver surface will be performed in
order to assess severe ﬁbrosis and/or cirrhosis. Addition-
ally, sonographic signs of portal hypertension will be
studied (splenomegaly, venous collaterals, portal vein
diameter and ﬂow, hepatic venous ﬂow, and the presence
of ascites).
To assess and quantify the grade of ﬁbrosis trained
technicians will perform elastography in all participants.
This test measures non-invasively and quantitatively the
liver stiffness using a probe which includes an ultrasonic
transducer transmitting a vibration wave through the liver.
The velocity of the ultrasonic wave correlates directly with
tissue stiffness [174, 175].
Determinants of interest
The association between factors known to inﬂuence liver
function and the occurrence of steatosis and ﬁbrosis will be
studied. Additionally the association of these conditions
with age, gender, nutritional intake, concurrent alcohol
intake, risk factors for viral hepatitis, BMI, waist-to-hip
ratio, serum glucose, insulin, and diabetes mellitus, serum
cholesterol and triglycerides will be studied. All clinical
information will be obtained by interview (updated with
liver speciﬁc questions) and clinical examination. For
recent EJE references see [176–183].
Neurological diseases
Objectives
Neuroepidemiologic research in the Rotterdam Study
focuses on the frequency, etiology and early recognition of
the most frequent neurologic diseases in the elderly,
including dementia, in particular Alzheimer disease, Par-
kinson disease and stroke. In neurodegenerative and cere-
brovascular disorders clinical symptoms typically become
manifest late in the disease course, the occurrence of
clinical disease does not reﬂect the underlying spectrum of
disease-related pathology, and most of the clinical syn-
dromes are etiologically heterogeneous. Therefore, an
additional research focus is on the causes and conse-
quences of pre-symptomatic brain pathology that can be
assessed with non-invasive modalities, which include
MR-imaging, neuropsychological testing and more
recently gait assessment.
Major ﬁndings
Neurodegenerative and cerebrovascular diseases are highly
frequent in the elderly. The prevalence increases from age
55 to 65 years to age 90 years and above from less than 1%
to over 40% for dementia [184], from less than 0.5% to
more than 4% for Parkinson disease [185], and from
approximately 1% to nearly 10% for stroke [186]. The
incidence ﬁgures follow this pattern of a strong increase
with age over the entire age range, with the age-speciﬁc
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women at least until the age of 85 [187] but with men
having a higher age-speciﬁc incidence of both stroke and
Parkinson disease than women throughout the age range
[186, 188].
Vascular pathology and vascular risk factors are asso-
ciated with worse cognitive performance [189], which also
translates in people with vascular pathology or risk factors
for vascular disease having an increased risk of dementia,
including Alzheimer disease [190]. Moreover, several life
style factors are associated with the risk of dementia and
Alzheimer disease [191–193], suggesting that onset of
dementia may at least partly be delayed or prevented.
Commonly used drugs may have a role in this [194].
Similar risk factor proﬁles also underlie cognitive decline
prior to the clinical diagnosis of dementia [195, 196].
The classical risk factors for stroke also predict risk of
stroke in the Rotterdam Study [197]. Novel risk factors,
including inﬂammatory markers, may be etiologically rel-
evant but thus far add little to the identiﬁcation of people at
risk http://www.ncbi.nlm.nih.gov/pubmed/17015791 [198].
Possibly underlying this is that a large amount of stroke
goes clinically undetected [199]. Nearly 20% of elderly
people have at least one silent brain infarct, and thereby a
nearly fourfold increased risk of clinical stroke, a more
than doubled risk of dementia including Alzheimer disease,
and an increased risk of depression [199].
With the advent of genome-wide association studies, the
Rotterdam Study has contributed to large-scale collabora-
tions and contributed to the identiﬁcation of novel genes
underlying the risk of Alzheimer disease and stroke
[200, 201].
Neuroimaging reveals that brain pathology is wide-
spread [202] and can go clinically undetected for a long
time. In addition to the silent infarcts, many apparently
healthy elderly have ischemic changes in their cerebral
white matter, i.e. white matter lesions, that are associated
with an increased risk of dementia, stroke and depression.
Also brain atrophy, especially of the hippocampus, is
already present years before onset of even the earliest sign
of cognitive impairment or subjective complaints. This
emphasizes the need to shift the attention in etiologic
research of neurodegenerative and cerebrovascular disease
to the causes of pre-symptomatic and underlying brain
changes. Technological advances in image acquisition,
optimized imaging sequences and automated post-
processing of multispectral MR data are major drivers of
the rapid developments in this ﬁeld. With our current
imaging protocol we can now not only investigate estab-
lished markers of brain pathology, such as infarcts, white
matter lesions, and atrophy, but also extend towards novel
markers, such as cerebral microbleeds and diffusion tensor
imaging (see further section on ‘‘Population imaging’’).
Methods update
Assessment of dementia and Alzheimer disease
In the baseline and follow-up examinations participants
undergo an initial screen for dementia with the Mini Mental
State Examination (MMSE) and the Geriatric Mental
Schedule (GMS), followed by an examination and infor-
mant interview with the Cambridge Examination for Mental
Disorders of the Elderly (CAMDEX) in screenpositives
(MMSE\26 or GMS[0), and subsequent neurological,
neuropsychological and neuroimaging examinations
[184, 187]. Of subjects who cannot be reexamined in per-
son, information is obtained from the GPs and the regional
institute for outpatient mental health care. A consensus
panel makes the ﬁnal diagnoses in accordance with standard
criteria (DSM-III-R criteria; NINCDS-ADRDA; NINDS-
AIREN).
Assessment of Parkinsonism and Parkinson disease
Participants are screened in the baseline and follow-up
examinations for cardinal signs of Parkinsonism (resting
tremor, rigidity, bradykinesia, or impaired postural reﬂexes).
Persons with at least one sign present are examined with
the Uniﬁed Parkinson’s Disease Rating Scale and a further
neurologic exam. PD is diagnosed if two or more cardinal
signs are present in a subject not taking antiparkinsonian
drugs, or if at least one sign has improved through medi-
cation, and when all causes of secondary Parkinsonism
(dementia, use of neuroleptics, cerebrovascular disease,
multiple system atrophy, or progressive supranuclear
palsy) can be excluded [185, 188].
Assessment of stroke and stroke subtypes
History of stroke at baseline was assessed through inter-
view and veriﬁed in medical records. Putative incident
strokes get identiﬁed through the linkage of the study
database with ﬁles from general practitioners, the munici-
pality, and nursing home physicians’ ﬁles, after which
additional information (including brain imaging) is col-
lected from hospital records. A panel discusses all potential
strokes and subclassiﬁes strokes into ischemic, hemor-
rhagic or unspeciﬁed [186, 198].
Assessment of cognitive function and motor function
Global cognitive function is measured through the Mini
Mental State Examination (MMSE) in all surveys. From
the third survey (RS-I-3) onwards we added a 30 min test
battery that was designed to assess executive function and
memory function, and which includes a Stroop test, a
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15 words Word List Learning test. This test battery was
expanded from the fourth survey onwards (RS-I-4) to
include motor function assessment using the Purdue Peg-
board Test. Moreover, from 2009 onwards we expanded
further by including the Design Orientation Test (DOT)
and a modiﬁed version of the International Cooperative
Ataxia Rating Scale (ICARS), which assess visuo-spatial
orientation and ataxia respectively [203, 204]. Halfway
through RS-III-1, we successfully implemented the
assessment of gait in all participants using the GAITRite
walkway (http://www.gaitrite.com/).
Rotterdam Scan Study: brain imaging within
the Rotterdam Study
In 1991, a random sample of 111 participants underwent
axial T2-weighted magnetic resonance (MR) imaging to
assess presence and severity of white matter lesions [205].
In 1995, a random sample of 563 non-demented partici-
pants underwent brain MR imaging in the context of the
Rotterdam Scan Study. From August 2005 onwards
(RS-II-2 and further), a dedicated 1.5 Tesla scanner is
operational in the research center of the Rotterdam Study,
and brain imaging is performed in all study participants
without contra-indications (see section on ‘‘Population
imaging’’). Currently, the follow-up of this latter sample
extends to up to 5 years. Therefore, in the coming years
we will be able to investigate how cerebral microbleeds
and DTI-markers relate to incident neurological diseases.
However, already cross-sectionally we have evidence that
these novel MRI markers relate to cognitive function and
motor speed [206]. For relevant recent EJE references see
[207–214].
Ophthalmic diseases
The ophthalmic part of the Rotterdam Study focuses on
frequency and risk factors of chronic ophthalmic diseases
and on ophthalmological characteristics of systemic dis-
eases. Our main research topics are age-related macular
degeneration, open angle glaucoma, myopia, and retinal
vessel diameters.
Major ﬁndings
Age-related macular degeneration (AMD)
During the last 5 years, international research strategies
were directed towards revealing the genetic background
of AMD. This has been very fruitful, and led to the
identiﬁcation of several genes which were consistently
replicated. Many more genes had been launched by small
studies and awaited validation. Our focus for AMD in
2010 was aimed at sorting out these relationships, as well
as identiﬁcation of gene-environment interactions. Work-
ing together with large consortia, we investigated the
proposed genes C5, SERPING1, and TLR3. None of these
genes appeared to show a consistent relation when studied
in large populations [215–218] The genetic associations
with the already known major genes, CFH and ARMS2,
remained without a doubt considerable; risks were
increased up to 10–15 times for individuals homozygous
for both risk variants. These genes point to complement
overactivation and oxidative stress as major pathways in
AMD pathogenesis.
Earlier in RS, we found that a diet rich in antioxidants
could lower the risk of early AMD. We now aimed to
assess whether this diet could also lower risks in persons
with a high genetic predisposition. This was indeed so,
persons with high risk variants and a high dietary intake of
beta-carotene, lutein and zeaxanthin, and omega-3 fatty
acids, had signiﬁcantly lower risks of early AMD than
those who were genetically predisposed but had low
intakes of these nutrients [219]. This biological interaction
was statistically signiﬁcant.
Research aims for 2012 and beyond are improving risk
estimates for (combinations of) risk alleles using incident
data from several population-based prospective studies;
evaluation of gene effects on subclinical manifestations of
disease, such as drusen on optical coherence tomography
(OCT); and more in depth investigation of gene-environ-
ment interactions.
Open angle glaucoma (POAG)
In contrast to AMD, the genetic background of POAG was
still largely unknown up to 2009. We aimed to elucidate
associated genes for optic disc parameters using the GWAS
platform in the RS I-III studies as well as the family-based
ERF population. These cohorts revealed two genome-wide
signiﬁcant loci for optic disc area, one near the CDC7 gene
and one near the ATOH7 gene; and two signiﬁcant loci for
vertical cup-disc ratio (VCDR), one in the CDKN2B gene
and one near the SIX1 gene. Meta-analysis with Twins UK
study conﬁrmed associations and launched several other
signiﬁcant loci. Interestingly, ATOH7 was also associated
with VCDR independent of optic disc area, suggesting a
common pathway [220]. In collaboration with a large
cohort from Singapore, these genes were validated and a
novel locus near CARD10 was found for optic disc area
[221].
Using the identiﬁed genes, we performed genetic risk
modeling, and found that a polygenic model best explained
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intra-ocular pressure (IOP) [222].
Non-genetic analyses were performed as well. We
studied incidence of glaucomatous visual ﬁeld loss during
10 years of follow up, and found that the overall incidence
rate of ﬁeld loss was 2.9 per 1,000 person-years, and that
the 10-year risk of GVFL was 2.8% (95% CI 2.3–3.4). We
determined whether lifestyle-related risk factors, such as
socioeconomic status, smoking, alcohol consumption, and
obesity, were associated with POAG, and found that
obesity was associated with a higher intraocular pressure
and a lower risk of developing POAG [223]. Future
investigations will focus on further elucidation of the
genetic background of POAG, risk modeling incorporating
all known risk factors, and study of gene-environment
interactions.
Myopia
Recently, we incorporated refractive error and myopia as a
disease outcome in the Rotterdam Study. Using the Illu-
mina platform, we performed a GWAS using the mean
spherical equivalent of both eyes as an outcome, and found
a signiﬁcant locus on chrom. 15q14, near the genes GJD2
and ACTC1 [224]. More comprehensive analyses showed
that variants in these genes could not explain the rela-
tionship, but that the associated region included regulatory
elements which may inﬂuence these genes. A collaborative
group in the UK found a locus on chromosome 15q25,
which we were able to replicate [225]. The plans for the
near future are a joint meta-analysis of virtually all studies
with refractive error and GWAS data, and an in depth
search for the causal variants at 15q14 by next generation
sequencing.
Retinal vessel diameters
One of the current goals was to ﬁnd genes which determine
retinal vessel diameters. Within the CHARGE consortium,
we found four novel loci associated with retinal venular
caliber one within the RASIP1 locus, one adjacent to VTA1
and NMBR, one in the region of ATXN2, SH2B3 and
PTPN11, and one adjacent to MEF2C [226].
Relationships with other disorders were investigated as
well. Retinal venular widening appeared to be associated
with an increased risk of vascular dementia [227]. We
evaluated the relationship with stroke and found that larger
retinal venular caliber was associated with an increased
risk for stroke, in particular with an increased risk for
intracerebral hemorrhage [228]. Lastly, we assessed whe-
ther smaller retinal arteriolar or larger venular calibers
were associated with incident late-life depression, and
found no evidence of an association. [229].
Methods update
At baseline and follow-up examinations participants undergo
ophthalmic measurements including best-corrected
ETDRS visual acuity, refractive error, Goldmann applana-
tion tonometry, keratometry, slit lamp examination of the
anterior segment and visual ﬁeld testing. In pharmacologi-
cal mydriasis we made 35 color photographs of the mac-
ular area, and 20 simultaneous stereoscopic imaging of the
optic disc and macular area. Since the ﬁfth follow-up,
35 stereoscopic color photographs of the optical disc and
the macular area were made (RS-I-5). Analog fundus
photography was replaced by stereoscopic digital imaging
of the macular area and optic disc since the third follow-up
examination. Optic nerve head analysis with a Heidelberg
Retina Tomograph, macular pigment density, and melanin
optical density measurements were added during the third
follow-up (RS-I-3). At ﬁfth follow-up examination, fourier
domain optical coherence tomography of the macular area
and optical disc, axial length and width measurements of
cornea, anterior chamber, lens, posterior chamber and
retina measured with Lensstar; and fundus autoﬂuores-
cence, infra-red and red-free measurements were added
(RS-I-5).
Classiﬁcation of AMD, POAG, and retinal vessel
diameters remained unchanged; refractive error was
evaluated as spherical value ? half cylindrical value,
following clinical standards.
Psychiatric diseases
Objectives
The aim of the psychiatric research in the Rotterdam Study
is to investigate the determinants, correlates and conse-
quences of common psychiatric problems in the elderly.
The focus has been on depressive disorders but anxiety
disorders, sleep disturbances, addiction to smoking, and
complicated grief are also being studied.
In the ﬁrst years of the Rotterdam Study (RS-I-1) psy-
chiatric data collection was very limited. However, in the
second visit most participants were screened for depressive
symptoms and from the third examination onwards, which
began in 1997, depressive symptoms and disorders have
been ascertained in all participants. An assessment of anx-
iety disorders, sleeping disturbances and complicated grief
were added in the fourth examination and have been
included in all follow-up visits of the Rotterdam Study I and
II, and in the baseline of the Rotterdam Study III. Recent
additions to the protocol include a screening for psychotic
symptoms and, starting with the third examination of the
Rotterdam Study II, ambulatory polysomnography.
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Psychiatric research in the Rotterdam Study focuses on
biological risk factors. The vascular depression hypothesis
was tested with different measures of atherosclerosis,
arterial stiffness and cerebral blood ﬂow [230]. We also
examined whether blood levels of vitamins and fatty acids,
immune parameters, and markers of folate metabolism
increased the likelihood of depression [231]. In one
ongoing project, diurnal patterns of cortisol secretion are
related to psychiatric and other disorders such as subclin-
ical atherosclerosis [232]. Studies of genetic polymor-
phisms and brain morphology are underway [233]. Current
data collection includes a dexamethasone suppression test
to measure hypothalamic–pituitary–adrenal axis activity in
all participants, which is unique in a population-based
study. Also, psychiatric problems and psychological traits
such as happiness, sleep duration and depression are
increasingly studied as determinants of health and mortal-
ity [234, 235].
Major outcomes
Information on depression is obtained from (a) psychiatric
examinations, (b) self-reported histories of depression,
(c) medical records, and (d) registration of antidepressant
use [236]. The psychiatric examination during follow-up
visits consists of a screening with the Center for Epide-
miologic Studies Depression Scale (CES-D), and in the
screen-positive participants a semi-structured interview
performed by a trained clinician (Schedules for Clinical
Assessment in Neuropsychiatry, [237]). To continuously
monitor incidence of depression throughout follow-up,
trained research-assistants scrutinize the medical records of
the general practitioners and copy the information about
possible depressive episodes.
The following anxiety disorders are assessed with a
slightly adapted Munich version of the Composite Inter-
national Diagnostic Interview: generalized anxiety disor-
der, speciﬁc and social phobia, agoraphobia without panic
disorder, and panic disorder [238, 239].
Sleep quality and disturbance is measured with the
Pittsburgh Sleep Quality Index. In addition, sleep duration
and fragmentation are assessed with actigraphy, a method
that infers wakefulness and sleep from the presence or
absence of limb movement [240]. In total, nearly 2,000
persons participated in this actigraphy study: they wore an
actigraph and kept a sleep diary for, on average, six con-
secutive nights. In 2011 we have begun to follow these
participants up with another 6 day assessment using ac-
tigraphy. In addition, 1,000 persons will receive one night
of polysomnography in their home setting.
The Inventory of Complicated Grief is used to identify
traumatic grief [241]. This is a condition distinct from
normal grief and bereavement-related depression, charac-
terized by symptoms like disbelief about the death and
searching for the deceased.
Major ﬁndings
Depression
Recently we completed our study of the incidence and
recurrence of depression [236]. During the follow-up per-
iod of 8 years on average, 566 depressive syndromes and
1,073 episodes of clinically relevant depressive symptoms
occurred. For depressive syndromes, the incidence rate was
7.0 (95% CI: 6.0–8.3) per 1,000 person-years and the
recurrence rate was 27.5 (95% CI: 23.7–32.1) per 1,000
person-years. The recurrence rate of depressive syndromes
was equal for women and men.
In a series of initial studies we found some evidence for
the vascular depression hypothesis. More severe coronary
and extra-coronary atherosclerosis were associated with a
higher prevalence of depression, as were cerebral haemo-
dynamic changes [230, 231]. However, our data did not
support a speciﬁc symptom proﬁle of vascular depression
as previously deﬁned [242]. Most importantly, we found no
longitudinal relation between peripheral atherosclerosis
and incident depression [243]. This study refutes the vas-
cular depression hypothesis that was largely based on
cross-sectional data. Prospective studies to test the vascular
hypothesis using cerebral imaging data are ongoing.
Sleep
Weinvestigatedtherelationshipsofsleepdurationwithboth
cardiovascular risk factors and psychiatric disorders. We
found a marked U-shaped association of actigraphically
measuredtotalsleeptimewithBMIandobesity[235].Sleep
fragmentation also increased the likelihood of a higher BMI
andobesity,although,intheveryoldsleepfragmentationisa
risk factor for low cholesterol levels [244]. We also inves-
tigatedandaimedtoexplainsexdifferencesinsubjectiveand
actigraphic sleep parameters [245]. If assessed by diary or
interview, elderly women consistently reported shorter and
poorer sleep than elderly men. In contrast, actigraphic sleep
measures showed shorter and poorer sleep in men. These
discrepancies were partly explained by sleep medication use
and alcohol consumption.
Anxiety
We found that prevalent anxiety disorders fulﬁlling DSM-
IV criteria may be much less co-morbid with depressive
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assessed with different diagnostic instruments. On the
other hand, a history of depression is very common in
persons with prevalent anxiety disorder (more than 50%;
[246]).
Smoking
Typically, determinants of smoking cessation are studied
by comparing former with current smokers [247]. We also
used a prospective approach of studying smoking cessation
in 1,200 smokers (mean years of smoking: 40 years, min-
imum: 10 years). Smoking status was repeatedly assessed
during follow-up every 3- to 4-years. Thus, an individual
could contribute any number of person-years to the
analyses. In other words, people were classiﬁed as smokers
or quitters on a day-by-day basis. This approach enabled us
to detect genetic effect on the incidence of smoking
cessation [248].
Complicated grief
In our population-based study of 5,741 elderly persons,
current grief was reported by 1,089 participants, and of
these 277 (25 or 4.8% of total) were diagnosed with
complicated grief, the vast majority of which had no
clinical symptoms of anxiety or depression. Persons with
complicated grief were older, had a lower level of educa-
tion, and more often had lost a child [249].
Genetics of common psychiatric disorders
In the past year, we have performed a series of genome-
wide association studies of the above psychiatric and
psychological phenotypes, mostly as part of the CHARGE
consortium. Whereas several analyses have yielded no
convincing genome wide signiﬁcant results—possibly
because initial studies were underpowered, psychiatric
phenotypes do not present very homogenous entities, or are
highly very multi-genetic—the genome wide analyses of
intermediate phenotype such as cortisol or behavioural
traits are more promising [250]. To study the genetics of
cortisol, we have established a dedicated consortium of
population-based studies: CORNET.
Finally, ongoing psychiatric research projects examine
whether and how psychological well-being or psychiatric
problems contribute to survival. Most importantly, we are
interested in whether the effects are speciﬁc to certain
behaviour or emotions, are independent of confounding
by physical disease, or can be explained by lifestyle,
immunological or hormonal regulation. For recent EJE
references see [251–259].
Respiratory diseases
Objectives
The objectives are to study the incidence of chronic obstruc-
tive pulmonary disease (COPD), to investigate genetic
and environmental risk factors for COPD, and to study the
effect of COPD on mortality. COPD is deﬁned as a disease
state characterized by airﬂow limitation that is not fully
reversible. The airﬂow limitation is usually both progressive
and associated with an abnormal inﬂammatory response of
the lungs to noxious particles or gases such as tobacco
smoke [260]. COPD is a worldwide leading and still
increasing cause of chronic morbidity and mortality that will
change from the sixth to the third most common cause of
death worldwide by 2020, whilst rising from fourth to third
in terms of morbidity [261].
Major ﬁndings
In the ﬁrst cohort of the Rotterdam Study (RS-I) of 7,983
participants, 648 cases were identiﬁed with incident COPD
afteramedianfollow-uptimeof11 years.Thisresultedinan
overall incidence rate of 9.2/1,000 person-years (PY) (95%
CI, 8.5–10.0). The incidence rate of COPD was higher
amongmen(14.4/1,000PY;95%CI,13.0–16.0)thanamong
women (6.2/1,000 PY; 95% CI, 5.5–7.0) and higher in
smokers than in never-smokers (12.8/1,000 PY; 95% CI,
11.7–13.9and3.9/1,000PY;95%CI,3.2–4.7,respectively).
Remarkable was the high incidence in the youngest females
in the age category of 55–59 years (7.4/1,000 PY; 95% CI,
4.1–12.6). For a 55 year-old man and woman, still free of
COPD at cohort entry, the risk to develop COPD over the
coming 40 years was 24 and 16%, respectively [260]. Since
COPD is not only affecting the lungs, but is also character-
isedbyextrathoracicmanifestations,anotherlineofresearch
focuses on the role of systemic inﬂammation in the patho-
genesis of COPD and its comorbidities. High levels of
hsCRP (3 mg/l), a marker of systemic inﬂammation, were
associated with a signiﬁcantly increased risk of incident
COPD (hazard ratio (HR), 1.7; 95% conﬁdence interval
(95% CI), 1.16–2.49) compared with persons with low CRP
levels (\1 mg/l). The risk remained increased after adjust-
ment for potential confounders and introduction of a poten-
tial latencyperiodof3 years. The risk was mostpronounced
for former smokers (HR, 2.2; 95% CI, 1.12–3.74). No CRP
singlenucleotidepolymorphismorhaplotypewasassociated
withasigniﬁcantlyincreasedordecreasedCOPDrisk[262].
Spirometric measures of lung function are heritable traits
that reﬂect respiratory health and predict morbidity and
mortality. We meta-analyzed genome-wide association
studies for two clinically important lung-function measures:
forced expiratory volume in the ﬁrst second (FEV1) and its
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airﬂow obstruction. This meta-analysis included 20,890
participants of European ancestry from four CHARGE
Consortium studies: Atherosclerosis Risk in Communities,
Cardiovascular Health Study, Framingham Heart Study
and Rotterdam Study. We identiﬁed eight loci associated
with FEV1/FVC (HHIP, GPR126, ADAM19, AGER-PPT2,
FAM13A, PTCH1, PID1 and HTR4) and one locus associ-
atedwithFEV1(INTS12-GSTCD-NPNT)atorneargenome-
wide signiﬁcance [P\5 9 10(-8)] in the CHARGE
Consortiumdataset[263].TheHedgehogsignallingpathway
plays an important role in lung morphogenesis and cellular
responses to lung injury. A genome-wide association study
has demonstrated that two single nucleotide polymorphisms
(SNPs) near the Hedgehog-interacting protein (Hip) gene,
SNP identiﬁers rs1828591 and rs13118928, are associated
with risk of chronic obstructive pulmonary disease (COPD).
We investigated the association between genetic variation
neartheHipgeneandCOPD,andwhetherriskestimateswere
modiﬁedbysmokingbehaviourintheRotterdamStudy.Both
SNPs were signiﬁcantly associated with risk of COPD (OR
0.80; 95% CI 0.72–0.91). Homozygosity for the minor G
allele resulted in a decreased risk of COPD of approximately
40%(95% CI 0.47–0.78). There was a signiﬁcant interaction
with the number of pack-years of smoking (P = 0.004). The
meta-analysis yielded an odds ratio for COPD of 0.80 per
additional G allele [P = 3.4 9 10(-9)]. Genetic variation
neartheHedgehog-interactingproteingenewassigniﬁcantly
associated with risk of COPD, depending on the number of
pack-years of smoking [264].
Methods update
Clinical assessment of COPD
For the validation of the COPD cases, we had access to
hospitaldischargeletters,ﬁlesfromthegeneralpractitioners,
spirometryreportsandpharmacydispensingdataforpatients
participating in the Rotterdam Study. Spirometry was per-
formed in the context of the ﬁrst Rotterdam cohort study
(RS-I) in 3,550 participants. In addition, throughout the
entire study period, spirometries were also performed on
clinical indication by respiratory specialists and internists
with a subspeciality in respiratory medicine. In the absence
of spirometry, all medical information of subjects who used
respiratory medication for at least 6 months and all hospital
discharge letters or mortality reports with a coded diagnosis
of COPD were reviewed. Deﬁnite COPD was deﬁned by a
moderate-to-severe obstructive spirometry (FEV1/FVC\
0.7andFEV1\80%predicted),and/orasCOPDdiagnosed
by a specialist in internal medicine (mainly respiratory
physicians or internists with a subspeciality in respiratory
medicine) based upon the combination of clinical history,
physical examination and spirometry. Probable COPD was
deﬁned by a mild obstructive spirometry (FEV1/FVC\0.7
and FEV1 C 80% predicted) and/or as COPD diagnosed by
a physician in another medical speciality (e.g., a general
practitioner). Clinical outcomes are collected during our
continuous follow-up and include respiratory and non-
respiratory death, hospitalisations due to exacerbations of
COPD as well as moderate to severe COPD exacerbations
treated with systemic corticosteroids and/or antibiotics. For
pulmonaryfunctiontestinginthe5throundoftheﬁrstcohort
oftheRotterdamStudy(RS-I-5),the3rdroundofthesecond
cohort (RS-II-3), and the 2nd round of the third cohort
(RS-III-2), more detailed and sophisticated techniques are
used to assess pulmonary function. Since COPD encom-
passes small airway disease (obstructive bronchiolitis) and
parenchymal destruction of the lungs (emphysema), both
components will be investigated by spirometry and mea-
surement of pulmonary diffusion capacity, respectively.
Spirometry
Spirometry is performed by trained paramedical personnel
using an electronic spirometer with pneumotachograph (Jae-
ger Masterscreen PFT, Cardinal Health, Hoechberg, Ger-
many), according to the American Thoracic Society (ATS)/
European Respiratory Society (ERS) guidelines. Forced
expiratoryvolumeinonesecond(FEV1),forcedvitalcapacity
(FVC) and FEV1/FVC ratio are measured; the spirogram
(volume-time curve) and maximal expiratory ﬂow-volume
curve are also recorded. The interpretation of spirometries is
performed independently by two research physicians; in case
of discordance between both physicians, a senior respiratory
physician decides. Measurement of pulmonary diffusion
capacity Measurement of diffusion capacity by single-breath
determination of carbon monoxide (CO) uptake in the lung
(DL,CO) assessesthe uptakeofcarbonmonoxide(CO)from
the lung over a breath-holding period [265]. The DL, CO is
measured using the Jaeger Masterscreen PFT Pro Diffusion
apparatus (Cardinal Health, Hoechberg, Germany) according
totheguidelinesoftheATS/ERStaskforceonstandardisation
oflungfunctiontesting[265].Thetestgasesusedtocalculate
DL, CO include a tracer gas (methane), to measure alveolar
volume (VA), as well as carbon monoxide (CO 0.3%). The
remainder of the test gas mixture includes O2 and N2.F o r
recent EJE references in this area see [266–279].
Genetic and biomarker studies
Objectives
The ﬁrst objective of the laboratory team is to collect, store
and manage the biological tissues mainly blood and urine
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group concerns genotyping and assessment of biomarkers.
Major ﬁndings
Among the biomarker analyses our study documenting the
relationship between homocysteine and osteoporosis was
novel [121] and has since been widely replicated. Across all
research lines in the Rotterdam Study, several candidate
gene studies have also yielded new insights coming from
both exploratory studies as well as from collaborative rep-
lication efforts. A unique feature of the Rotterdam Study is
exploited by studying the relationship between pleiotropic
gene variants and multiple diseases and disease related
endpoints. For example, the studies on the promoter region
of the IGF-1 gene revealed a series of consistent associa-
tions ranging from birth weight to diabetes [280], while
other consistent associations involve the estrogen receptor
alpha (ESR1) gene in relation to osteoporosis [281],
osteoarthritis, height, myocardial infarction [282], age-at-
menopause, and depression. Rotterdam Study investigators
are playing leading roles in the emerging large global
consortia focussed on assessing the contribution of complex
disease gene variants by prospective meta-analysis across
many epidemiological cohorts [283], such as CHARGE,
ENGAGE and the GENOMOS/GEFOS [284, 285]. Since
2005 the genome wide association study (GWAs) has
changed the ﬁeld of complex genetics, and identiﬁed an
ever growing list of common variants contributing to dis-
ease risk and explaining genetic variance of traits. Initial
ﬁndings in the Rotterdam Study from individual collabo-
rations replicating early GWAs hits included CFH in age-
related macula degeneration [286], NOS1AP in QT interval
[287], and several SNPs involved in height, type 2 diabetes,
and breast cancer (collaboration with WTCCC investiga-
tors). The Rotterdam Study has generated GWAs data for
almost the complete dataset summing to over 11,000 DNA
samples, and is involved as a major collaborative centre for
meta-analysis studies of GWAs data, including national
programs (RIDE, NGI-NCHA), EU-funded projects
(GEFOS, TREATOA, ENGAGE), and voluntary collabo-
rations (GIANT, MAGIC, CHARGE). Especially, from the
CHARGE consortium (the Rotterdam Study together with
the Framingham Study, AGES, CHS, and ARIC) many
important publications have emerged on a wide variety of
phenotypes and diseases from all major research lines in the
Rotterdam Study [288–292].
Data collection, storage and management
At each examination, blood, serum, plasma (citrate, hep-
arine, and EDTA based), sputum, and urine are collected.
Fasting blood samples are collected along with challenged
samples as part of a glucose tolerance test. Sputum is
collected before and after a dexamethasone-suppression
test. Sputum is frozen at -196C before and after the
challenge and stored at -80C. To obtain serum and
plasma, tubes are centrifuged according to a protocol
standardising time and conditions from the drawing of
blood to centrifugation. All samples are snap frozen at
-196C using liquid nitrogen and stored at -80C. RNA is
isolated from blood within 5 h after sampling and stored at
-20C. DNA is isolated from blood and extraction has
been recently automated using a Hamilton STAR pipetting
platform and AGOWA magnetic bead technology. DNA
sample storage is in Matrix 2D-barcode tubes in 96 well
format. Overnight urine samples are collected, frozen at
-196C and stored at -80C. For data management, an
in-house customized laboratory management system has
been developed. Sample retrieval will be automated with
an in-house customized laboratory track and trace system.
Blood assessments
For all participants, serum cholesterol, HDL, LDL, tri-
glycerides, glucose and glucose levels are assessed. In
urine, micro albumin and creatinine are determined in all
participants. There have been a large number of speciﬁc
blood/serum/plasma-based biomarker assessments, includ-
ing steroids (e.g., estrogens, androgens, vitamin D, corti-
sol), interleukins, CRP, IGF1, insulin, iron-parameters
(iron, ferritin and transferrin saturation), ﬁbrinogen, homo-
cysteine, folic acid, riboﬂavine, pyridoxine, SAM/SAH
ratio, cobalamine, Lp-PLA2, Fas/Fas-L, vitamins, abeta42/
40 and thyroid hormones (TSH).
Genotyping facilities
Afﬁliated laboratory facilities include a medium/high-
throughput platform for candidate genes studies and GWAs
analyses. The facilities use high-end automated machinery
including a Caliper/Zymark ALH 3000 pipetting robot
(including a TwisterII, and integrated plate sealer, plate
reader (OD 260/280), a Tecan EVO 150 Freedom pipetting
robot, a Deerac Equator NS808 nanoliter liquid dispenser,
15 electronic PCR machines (ABI 9700, 2 9 384), an
ABI7900HT Taqman machine (running 1 ng gDNA in 2l
reactions), a WAVE 3500HT dHPLC, Sequenom iPlex,
and two ABI3100 sequencing machines. DNA sample
handling is centred on 384-well plates. Candidate gene
studies are done mostly using Taqman and Sequenom
genotyping with throughputs at 30,000 genotypes per day.
Continuous efforts are focussed on reducing the required
amount of genomic DNA which is now down to 1 ng per
genotype. GWAs genotyping studies are based on 500 K
Affymetrix arrays (a pilot project of 450 women) and 550
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Study cohort encompassing over 11,000 DNA samples.
The in-house GWAs genotyping facility has been partly
sponsored by NWO investment grants (911-03-012;
175.010.2005.011), is part of the Erasmus Medical Center
Biomics core facility, and serves as knowledge center for
polymorphism analysis attracting national and international
interested parties, both academic and industrial.
Candidate gene studies
We have genotyped over 300 individual polymorphisms as
part of candidate gene studies across the complete cohort
and conducted a large number of candidate gene studies in
the Rotterdam Study. These mostly concern individual
potentially functional single nucleotide polymorphisms
(SNPs) per gene, but sometimes also haplotype tagging
(delete space) SNPs (e.g., ESR1, ESR2, HSD11B1,
ﬁbrinogen), and also high density SNP screening (e.g., the
vitamin D receptor gene). The candidate genes studied
include the apolipoprotein E gene (APOE), the angioten-
sin-converting enzyme (ACE), the gene encoding angio-
tensinogen (AGT), angiotensin II type 1 receptor (AT1R)
gene, G protein beta3 (GNB3), adducine gene, Cholesteryl
Ester Transfer Protein (CETP), Hepatic Lipase, Phospho-
diesterase 4D (PDE4D), ALOX5AP encoding 5-lipoxyge-
nase activating protein, a polymorphism in the regulatory
region of the Insulin-like Growth Factor 1 (IGF-1) gene,
the hemochromatosis (HFE) gene, Complement factor H
gene (CFH), and several polymorphisms in genes from the
estrogen-, thyroid-, cortisol-, vitamin D-, IGF-, and Wnt
signalling pathways, the homocysteine pathway, and sev-
eral matrix molecules.
Genome wide association studies (GWAs)
Genome Wide Association studies (GWAs) are based on
genotyping epidemiological cohorts with ultra-high density
SNP arrays with up to 1 million SNPs. The method has
been shown to successfully identify common genetic fac-
tors for hundreds of traits and diseases (see www.genome.
gov/ GWAstudies). Through a large grant from the Dutch
research organisation NWO one of the world’s largest
GWAs datasets has been facilitated involving over 11,000
DNA samples from the Rotterdam Study cohorts. This
GWAs dataset is based on the Illumina 550 and 610 K
arrays and will be useful for all research lines within the
Rotterdam Study. In addition, it will also serve as a control
GWAs dataset for other research centers in and outside The
Netherlands for both SNP frequencies as well as copy
number variations (CNVs). In addition our group has also
been active in developing new software for GWAs analyses
[292].
New developments
The new development in the basic sciences will be to move
to transciptomic studies and proteomic studies. With this
view, the data collection protocol has been adjusted, stan-
dardizing blood collection. For recent EJE references see
[290–310].
Pharmaco-epidemiologic studies
Objectives
A major objective of the pharmaco-epidemiologic studies
is to investigate the role of drugs as determinants of disease
in the Rotterdam Study. This includes studying efﬁcacy
and effectiveness of drugs, as well as adverse reactions to
drugs.
Major ﬁndings
Important ﬁndings have been published on pharmaco-epi-
demiological topics concerning the main outcomes in the
Rotterdam Study. Studies about the association between
dementia, and antihypertensive drugs [293] and NSAIDs
[194] have strongly suggested a protective effect of both
groups of drugs. However, beta-blockers were associated
with an increased risk of depression [294]. Several studies
have been performed on cardiovascular topics [62, 295,
296]. In one of these studies, NSAIDs were associated with
an increased risk of heart failure. A recent study demon-
strated that short-term use of NSAIDs is associated with
transient impairment of echocardiographic parameters
[297]. In line with the suspicion that QTc-prolonging drugs
may cause sudden cardiac death, it was demonstrated in the
Rotterdam Study that a prolonged QTc is indeed an
important risk factor [62]. Non-cardiovascular drugs which
inhibit hERG-encoded potassium channels were associated
with an increased risk of sudden cardiac death [298].
Furthermore, in one study it was demonstrated that high-
dose corticosteroids increase the risk of atrial ﬁbrillation
[296]. In how far this effect is modiﬁed by susceptibility
markers on chromosome 4q25 [299] or on KCNN3, a gene
of which variants were associated with lone atrial ﬁbrilla-
tion in a meta-analysis in the Rotterdam Study and several
cohorts from the USA [300], is currently being investi-
gated. Other important susceptibility genes for PR-interval
[59], resting heart rate [301] and QRS duration [302] may
prove to be important effect modiﬁers for drug effects. In
the important area of locomotor diseases, studies have
demonstrated that thiazide diuretics protect against hip
fracture [303] and that statins reduce the risk of vertebral
fracture [304]. On the other hand, the risk that long-term
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thritis has been emphasized [305]. In the area of ophthal-
mic diseases, a protective effect of cholesterol-lowering
agents on macular degeneration has been studied [306,
307]. In other areas, such as pharmacogenetics and other
causes of interactions between drugs, several important
ﬁndings have been published [287, 308–328]. In this
regard, there proved to be important genetic variations in
OCT1 and MATE1 transporters with consequences for
metformin response in diabetics [329]. Genetic variation in
the OCT1 transporter was also associated with response
and survival time in users of drugs against Parkinsonism
[330]. Interesting were the results of a GWA in users of the
anticoagulant phenprocoumon which conﬁrmed the
important genetic variant for VKORC1, CYP2C9 and 4F2
[331]. An increasingly important topic is the association
between long-term drug use and cancer. In the Rotterdam
Study, high-ceiling diuretics were associated with an
increased risk of basal cell carcinoma [332]. The impor-
tance of cytochrome P450 enzymes as effect modiﬁers was
underlined by 2 studies, one of which showed increased
survival in breast cancer patients on tamoxifen with a
CYP2C19*2 polymorphism [333, 334].
Methods update
For several reasons, a drug is a highly attractive determi-
nant in clinical epidemiologic research. First, drugs are
probably the most important therapeutic intervention in
health care. Despite rigorous clinical research before reg-
istration, many important effects of drugs are discovered
after marketing. Second, all marketed drugs have proven
biological activity, meaning that it concerns a determinant
which really matters. Third, and as a consequence of the
availability of complete medication histories in Dutch
health care, the role of drug exposure can be assessed in a
detailed way. In the Rotterdam Study, there is an almost
complete coverage of the population as of January 1, 1991,
thanks to the fact that all pharmacies which serve the
Ommoord district are on one computer network. To date,
more than three million prescriptions have been delivered
to the population of the Rotterdam Study and of each
prescription, details are available about the product name
and contents, ATC-code, dosage and duration of drug
therapy. This facilitates the use of detailed analyses with
the drug as a time-varying determinant [335]. Drugs are a
group of determinants which can be studied in association
with a large variety of diseases. In the Rotterdam Study
there is a strong interest in the association between drugs
and the cardiovascular, neurological, endocrine, and oph-
thalmic diseases which have been the main topics since its
start. However, there is also important information about
the association with psychiatric diseases, cancer, and
chronic obstructive pulmonary disease. Moreover, impor-
tant information about secondary outcomes, such as drug
blood levels, other laboratory information, and information
about hospital discharge diagnoses, is gathered on a con-
tinuous basis to facilitate pharmaco-epidemiological stud-
ies. Further EJE references can be found in [336–342].
Imaging studies
Objectives
Biomedical imaging allows for non- or minimally-invasive
assessment of structural and functional changes that may
reﬂect speciﬁc pathology. Recent developments in image
data acquisition and analysis enable to use these techniques
on a large scale. The Population Imaging Unit within the
Rotterdam Study aims to assess imaging biomarkers of
disease in a pre-symptomatic phase at the population level.
Advantages of imaging measures include that they mark
early disease, can be assessed reliably and reproducibly,
and are quantitative rather than qualitative which makes
them more powerful than most conventional outcome
measures such as clinical phenotypes. The main imaging
modalities that are currently being applied in the Popula-
tion Imaging Unit are multidetector computed tomography
(MDCT) and magnetic resonance imaging (MRI).
Imaging infrastructure and storage
MDCT
CT imaging is currently performed with hospital-based
16-slice or 64-slice MDCT scanners (SOMATOM Sensa-
tion 16 or 64, Siemens, Forcheim, Germany), located at
Erasmus University Medical Center. Scanners are operated
by clinical technicians. CT images are acquired without
contrast-enhancement and according to standardized pro-
tocols. Imaging data are transferred from the CT scanner to
a securely backed-up research picture archiving system.
MRI
From August 2005 onwards, a dedicated 1.5 Tesla MRI
scanner (GE Healthcare, Milwaukee, Wisconsin, USA) is
operational in the Rotterdam Study research center. This
scanner is operated by trained research technicians and all
imaging data are collected according to standardized
imaging protocols. Changes or updates in hardware or
software conﬁguration are avoided and regular quality
checks are performed to secure validity of cross-subject
and cross-scan comparisons. Imaging is performed without
administration of contrast agents. All imaging data are
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University Medical Center. Data are stored on a securely
backed-up research picture archiving system, using pro-
grammed scripts to check for completeness of the data
received.
Data management and processing
Assessment of incidental ﬁndings
All imaging data are visually evaluated within days after
acquisition by trained physicians for the presence of clin-
ically relevant incidental ﬁndings [202, 343]. Expert radi-
ologists are consulted for all abnormal ﬁndings and the
management of clinically relevant ﬁndings is based on
protocols deﬁned by expert panels. These protocols are
updated on a regular basis incorporating the current best
available knowledge regarding treatment and prognosis of
the various abnormalities discovered.
Automated processing of MRI data
Though some measurements are still performed manually
or scored visually, the majority of imaging data is now
processed using semi- and fully-automated computer
algorithms. The Population Imaging Unit collaborates with
the Biomedical Imaging Group Rotterdam (BIGR) of
Erasmus University Medical Center in the application and
development of automated processing pipelines for high-
throughput of large data quantities. These pipelines com-
prise on the one end image quality checks and procedures
for non-uniformity correction, normalization and image
registration and on the other end advanced algorithms to
extract image features to use for analyses. Grid architec-
tures and networked processing pipelines are used to pro-
cess the large quantities or imaging data that are acquired
in the Rotterdam Study.
Major ﬁndings
The Rotterdam Study research lines currently applying
imaging within the Population Imaging Unit are those on
neurological diseases and cardiovascular diseases.
Brain imaging (MRI)
Neurodegenerative and cerebrovascular disease are com-
mon disorders in the elderly that exert a large inﬂuence on
brain functioning. Identifying underlying pathology in a
preclinical state may help to recognize persons at risk,
assess determinants of disease and develop preventive
measures. Main objective for the Population Imaging Unit
with respect to brain imaging is therefore to identify and
quantify brain imaging biomarkers that mark the develop-
ment of neurodegenerative and cerebrovascular disease.
From August 2005 onwards (RS-II-2 and onwards),
brain imaging in the Population Imaging Unit is performed
in all study participants without contra-indications in the
context of the Rotterdam Scan Study. The current scanning
protocol includes 4 high-resolution axial sequences (3D
T1-weighted; 2D PD-weighted; 2D FLAIR; and 3D T2*
GRE), 2D phase-contrast imaging, and diffusion tensor
imaging (DTI). Total scanning time amounts to approxi-
mately 30 min. Currently, over 5,000 unique brain MRI
scans and over 800 follow up scans after a time interval of
three to 4 years have been acquired.
Fully automated methods are applied to quantify atrophy
of brain tissues and structures and the severity of white
matter lesions [343–345] Automated hippocampal seg-
mentation has been successfully applied on multi-scanner
acquired MR images (on scans acquired in the Rotterdam
Scan Study in 1995 [346] and follow up examinations in
2006), showing that a decline in hippocampal volume over
a 10-year follow up period predicted onset of clinical
dementia [347].
Phase-contrast imaging allows for assessment of blood
ﬂow in the carotids and basilar artery. This yields measures
of total brain perfusion [348], which when lower was found
to be relate to worse cognition, an association that is
mediated by brain atrophy [349].
The 3D T2* GRE sequence that we use was speciﬁcally
developed to increase the conspicuity of cerebral micro-
bleeds [350]. With this optimized sequence, we found that
microbleed prevalence gradually increases with age, from
6.5% in persons aged 45–50 years to 35.7% in participants
of 80 years and older; and that overall, 15.3% of all sub-
jects over the age of 45 years has at least 1 microbleed; a
much higher prevalence than was reported before
[351, 352]. We found supportive evidence that deep or
infratentorial microbleeds reﬂect arteriolosclerotic angi-
opathy, whereas strictly lobar microbleeds are caused by
cerebral amyloid angiopathy [351, 352]. We furthermore
recently demonstrated that incidence of microbleeds over a
3-year time interval is high and that risk factors for new
microbleeds again differ according to microbleed location,
in line with our ﬁndings regarding prevalent microbleeds
[353]. These ﬁndings impact research into the causes of
cerebral amyloid angiopathy, as well as fuel the ongoing
discussion about the safety of antithrombotic therapy in
persons with microbleeds [354, 355].
Diffusion tensor imaging (DTI) allows the assessment of
the microstructural integrity of white matter. White matter
microstructure loses its integrity with increasing age, but
this can largely be explained by presence of white matter
atrophy and white matter lesions [356]. Nevertheless, the
microstructural integrity in the normal appearing white
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function regardless of concurrent macrostructural changes,
emphasizing the importance of the microstructural integrity
of white matter [206]. Recent advances in image process-
ing now allow us to quantify the degree of connectivity
between brain regions [357], enabling the further explo-
ration of structural integrity in relation to functional pro-
cesses in aging.
Imaging of atherosclerotic calciﬁcations (MDCT)
Main objectives with respect to imaging of vascular cal-
ciﬁcations are to investigate distribution of and risk factors
for atherosclerotic calciﬁcations in the general elderly
population and to study prognosis associated with calciﬁ-
cations in different vessel beds.
From September 2003 until February 2006, all partici-
pants from RS-I-4 and RS-II-2 who completed a center
visit were invited to a MDCT scan of the coronary arteries
and a second scan of the aortic arch and carotid arteries. A
total of 2,521 participants (response rate 79%) were scan-
ned. The cardiac scan reached from the apex of the heart to
the tracheal bifurcation. The second scan reached from the
aortic arch to the intracranial circulation. Images were
analyzed by trained reviewers and calciﬁcation in the dif-
ferent vessel beds (coronaries, aortic arch, extracranial and
intracranial carotids) were quantiﬁed using the Agatston
score [358].
As expected, we found that calciﬁcation load was higher
overall in men compared to women, though aortic arch
calciﬁcation was more prevalent among women [359]. Age
and current smoking were found to be the strongest inde-
pendent risk factors for arterial calciﬁcation [360]. Fur-
thermore, strong and graded associations of prevalent
stroke were found with carotid artery, aortic arch and
coronary artery calciﬁcation, independent of cardiovascular
risk factors [361]. We are currently investigating the rela-
tion between arterial calciﬁcation in various vessel beds
and ischemic brain disease on MRI.
Carotid plaque imaging (MRI)
Carotid wall thickening and atherosclerosis are highly pre-
valent at older age and are considered a major cause of
cerebrovascularevents[197].Carotidatheroscleroticplaque
constituents such as lipid core and hemorrhage, so-called
‘‘vulnerable’’ components, are considered important factors
in development of clinical neurological events [362]. With
MRI, it is possible to separately identify these plaque com-
ponents [363]. Main objectives with respect to carotid
imaging in the Rotterdam Study are to investigate distribu-
tion of and risk factors for carotid plaque components in the
general elderly population and to studyprognosis associated
with speciﬁc carotid plaque composition.
From October 2007 onwards, all participants with car-
otid wall thickening of 2.5 mm or larger on ultrasound
(approximately 25% of the Rotterdam Study population)
are invited for carotid MRI. Imaging is performed with a
bilateral phased-array surface coil (Machnet, Eelde, The
Netherlands), stabilizing subjects in a custom-designed
head holder to reduce motion. The imaging protocol con-
sists of a series of high-resolution MRI sequences to image
the carotid bifurcations on both sides: a PDw Fast Spin
Echo (FSE) Black-blood (BB) sequence; a PDw-FSE-BB
with an increased in-plane resolution; a PDw-Echo Planar
Imaging (EPI) sequence and a T2w-EPI sequence; and 2
three-dimensional (3D) sequences: a 3D-T1w-Gradient
Echo (GRE) sequence; and a 3D phased-contrast
MR-Angiography. Total scanning time amounts to
approximately 30 min. Plaques are reviewed by trained
raters for the presence of three different plaque components
(calciﬁcation, hemorrhage and lipid core). Furthermore,
carotid plaque size is quantiﬁed by obtaining maximum
carotid wall thickness and degree of luminal stenosis using
the NASCET criteria [364] on the PDw-FSE images.
Postprocessing techniques aimed at automated quantiﬁca-
tion of plaque volume and identiﬁcation of different plaque
components are currently being developed. So far, over
1,300 participants underwent a complete carotid MRI scan
and data are currently being analyzed. There is a complete
overlap between carotid and brain MRI participants,
allowing for the investigation of carotid plaque constituents
in relation to brain imaging markers.
New developments
New developments to be expected within the Population
Imaging Unit are on the one hand implementation of new
imaging methods and on the other hand to integrate imaging
data with other available data such as genetic data. Also,
focus will shift from purely structural imaging to also
including functional imaging data, e.g. by incorporating
functional MRI into the brain imaging protocol. Further-
more, besides ever-increasing advances in imaging hard-
ware, software and sequence design, major advances are to
be expected from (fully) automated image analysis. Com-
puter processing of images will enable to make use of all
information contained within the image, introducing new
imaging biomarkers. Besides, the vast amount of imaging
data that are acquired in population-based studies like the
Rotterdam Study renders visual assessment or manual
measurements virtually impossible, strengthening the need
for (fully) automated methods of data extraction and anal-
ysis. For recent EJE references see [182, 365–369].
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The Rotterdam Study is directed by a Management Team
comprising the scientiﬁc principal investigators Cornelia
van Duijn (PI Genetic epidemiologic studies), Oscar
Franco (PI Cardiovascular diseases), Albert Hofman
(chairman, PI Rotterdam Study), Arfan Ikram (PI Neuro-
logical diseases), Harry Janssen (PI Hepatic diseases),
Caroline Klaver (PI Ophthalmic diseases), Ernst Kuipers
(PI Internal Medicine), Tamar Nijsten (Dermatological
diseases), Bruno Stricker (PI Pharmaco-epidemiology),
Henning Tiemeier (PI Psychiatric diseases), Andre ´ Uitter-
linden (PI Genomic studies), and Meike Vernooij (PI
Population Imaging); and Jan Heeringa, MD, PhD, study
coordinator, Eric Neeleman, head IT, and Frank van Rooij,
DSc, head data-management. The study of respiratory
diseases is conducted in close collaboration with Prof Guy
Brusselle, Department of Respiratory Medicine, University
of Gent, Belgium.
The following persons are Principal Investigator Emer-
itus of the Rotterdam Study: Frank van den Ouweland (PI
Internal Medicine 1990–1992), Diederick Grobbee (PI Car-
diovascular diseases 1990–1996), Albert Hofman (PI
Neurological diseases 1990–1996), Paulus de Jong (PI
Ophthalmic diseases 1990–2005), Huibert Pols (PI Internal
Medicine 1993–2006), Monique Breteler (PI Neurological
diseases 1997–2010), Gabriel Krestin (PI Population
Imaging 1998–2010), Johannes Vingerling (PI Ophthalmic
diseases 2005–2010), Jacqueline Witteman (PI Cardiovas-
cular diseases 1997–2011).
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